The Chinese public demonstrates a relatively high level of awareness and a moderately favorable acceptance of XTx. However, respondents exhibit incomplete knowledge of inherent residual risks, immune rejection, and long-term efficacy in XTx. At the same time, they hold overly optimistic expectations regarding its therapeutic outcomes and associated costs.
Kuang et al. (Sun,) studied this question.